Your session is about to expire
← Back to Search
Chemotherapy + Radiation for Brain Cancer
Study Summary
This trial is studying how well temozolomide and radiation therapy work in treating patients with IDH wildtype lower grade gliomas or non-histological molecular glioblastomas.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 175 Patients • NCT01055314Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread to the lining of my brain and spinal cord.I must have an MRI with contrast for my radiation therapy plan.I was hospitalized for heart failure that affects my daily activities within the last year.My diagnosis is either gliosarcoma (grade IV) or pilocytic astrocytoma (grade I).I am currently on IV antibiotics for a bacterial or fungal infection.I have a serious heart rhythm problem that is not well-controlled.I do not have a severe lung condition that requires hospital care right now.I have severe kidney disease requiring dialysis.You have certain conditions like lupus or scleroderma that may increase your risk of side effects from radiation treatment, according to your doctor's opinion.My brain tumor is a type of glioma that is not IDH mutated.I haven't had serious wounds, ulcers, fractures, or major surgeries in the last 28 days.My hemoglobin level is at least 10.0 g/dl, possibly after a transfusion.I have been cancer-free for at least 3 years, except for non-dangerous skin cancers.I do not have liver problems causing jaundice or blood clotting issues.I have had or will have detailed MRI scans for treatment planning.I haven't been hospitalized for heart issues like unstable angina or heart failure in the last 6 months.I had a major heart attack in the last 6 months, confirmed by an EKG.My brain tumor is a high-grade glioma or glioblastoma without IDH mutation.You have a weakened immune system from a serious health condition.I have had chemotherapy or radiotherapy for a brain tumor before.You are not able to have an MRI scan with and without a special dye.You have a serious health condition that is currently causing you a lot of problems.I have had radiation therapy to my head or neck before.I can care for myself and perform normal activities with minimal assistance.My brain cancer is present in multiple areas.
- Group 1: Treatment (temozolomide, radiation therapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies available for this clinical trial?
"Affirmative. Clinicaltrials.gov exhibits that this clinical trial, initially posted on January 30th 2020 is actively recruiting participants. A total of 40 individuals need to be enlisted from a single medical facility for the study's continuation."
What is the maximum capacity of participants for this medical trial?
"Affirmative. The information stored on clinicaltrials.gov indicates that this medical trial, which was originally published in January 2020, is actively enrolling patients. A total of 40 participants are required at a single research site."
In what medical setting is Temozolomide usually prescribed?
"Temozolomide is typically prescribed to treat nitrosourea therapy, but it also has applications in treating advanced directives, refractory mycosis fungoides, as well as refractory neuroblastoma."
Has Temozolomide been researched in any other experiments?
"As of now, 207 clinical trials have been launched to study Temozolomide with 24 in the third phase. The majority are located near Seoul Songpa, but there are 4752 research centers running studies around this drug."
Does Temozolomide carry any adverse effects for individuals?
"The safety of Temozolomide was evaluated as a 2 on our Power scale, since the trial is only in Stage 2 and has evidence that bolsters its safety profile but no efficacy data."
Are any of the findings from this research groundbreaking?
"Temozolomide has been a subject of medical research since 2002, starting with an initial study conducted by Schering-Plough. This 60 patient trial granted the drug Phase 2 approval and triggered many other clinical trials; at present there are 207 studies involving this medication in 36 nations over 935 cities."
Share this study with friends
Copy Link
Messenger